Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Walvax Biotechnology Co., Ltd.
  6. Summary
    300142   CNE100000WN2

WALVAX BIOTECHNOLOGY CO., LTD.

(300142)
  Report
End-of-day quote Shenzhen Stock Exchange  -  2022-09-29
37.10 CNY   +0.49%
09/30A Chinese mRNA COVID vaccine is approved for the first time - in Indonesia
RE
09/29Indonesia to produce Chinese mRNA COVID vaccine locally - drugs agency
RE
09/16Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on March 19, 2022.
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
09/26/2022 09/27/2022 09/28/2022 09/29/2022 09/30/2022 Date
35.8 37.33 36.53 36.92 37.1 Last
20626370 21671730 12132990 20223200 19017460 Volume
-4.91% +4.27% -2.14% +1.07% +0.49% Change
Estimated financial data (e)
Sales 2022 6 506 M 914 M 914 M
Net income 2022 1 203 M 169 M 169 M
Net cash position 2022 2 095 M 294 M 294 M
P/E ratio 2022 49,5x
Yield 2022 0,30%
Sales 2023 7 771 M 1 092 M 1 092 M
Net income 2023 1 467 M 206 M 206 M
Net cash position 2023 2 646 M 372 M 372 M
P/E ratio 2023 40,3x
Yield 2023 0,49%
Capitalization 59 539 M 8 369 M 8 369 M
EV / Sales 2022 8,83x
EV / Sales 2023 7,32x
Nbr of Employees 1 237
Free-Float 27,6%
More Financials
Company
Walvax Biotechnology Co. specialises in the research, development, manufacturing and marketing of human vaccines. Products include vaccines against haemophilus influenzae, meningitis, septicaemia, meningococcal disease, etc. 
Sector
Pharmaceuticals
Calendar
10/13 | 02:00amShareholder meeting
More about the company
Ratings of Walvax Biotechnology Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about WALVAX BIOTECHNOLOGY CO., LTD.
09/30A Chinese mRNA COVID vaccine is approved for the first time - in Indonesia
RE
09/29Indonesia to produce Chinese mRNA COVID vaccine locally - drugs agency
RE
09/16Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on Mar..
CI
09/16Walvax Biotechnology Co., Ltd.'s Equity Buyback announced on March 19, 2022, has expire..
CI
09/01Walvax Gets Nod to Launch Clinical Trials of Two COVID-19 Vaccines
MT
08/10Walvax Biotechnology to Issue $184 Million of Convertible Bonds to Fund New Projects
MT
08/10Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30..
CI
08/10Walvax Biotechnology Co., Ltd. announced that it expects to receive CNY 1.2 billion in ..
CI
07/01Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on Mar..
CI
06/30Walvax Biotechnology Buys Back 170,000 Shares; Stock Rises 3%
MT
06/02Walvax's COVID-19 Vaccine Candidate Stronger Against Omicron Versus Sinovac's Jab
MT
04/28Walvax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended Mar..
CI
04/13Walvax Biotechnology Co., Ltd. Approves Cash Dividend for 2021
CI
04/01Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on Mar..
CI
03/21Walvax Biotechnology Slashes 2021 Dividend by 46% as Full-Year Profit Plunges 57%
MT
More news
News in other languages on WALVAX BIOTECHNOLOGY CO., LTD.
09/30Una vacuna china de ARNm contra el COVID logra su primera aprobación, en Indonesia
09/01Walvax obtient le feu vert pour lancer les essais cliniques de deux vaccins COVID-19
08/10Walvax Biotechnology va émettre des obligations convertibles d'une valeur de 184 millio..
08/10Walvax Biotechnology Co., Ltd. annonce ses résultats pour le semestre clos le 30 juin 2..
06/30Walvax Biotechnology rachète 170 000 actions ; l'action augmente de 3 %.
More news
ETFs positioned on WALVAX BIOTECHNOLOGY CO., LTD.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
VanEck Vectors ChinaAMC SME-ChiNext ETF - USD2.18%-0.71%-China
KraneShares MSCI All China Health Care Inde...1.28%4.79%China
KraneShares Emerging Market Healthcare Inde...1.21%4.18%NC
Global X MSCI China Health Care ETF - USD0.66%4.45%China
Xtrackers Harvest CSI300 1D - USD0.48%1.84%China
More ETFs positioned on WALVAX BIOTECHNOLOGY CO., LTD.
Chart WALVAX BIOTECHNOLOGY CO., LTD.
Duration : Period :
Walvax Biotechnology Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WALVAX BIOTECHNOLOGY CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Last Close Price 37,10 CNY
Average target price 33,00 CNY
Spread / Average Target -11,1%
EPS Revisions
Managers and Directors
Run Sheng Jiang President & Director
Hua Zhou Chief Financial Officer
Yun Chun Li Chairman & Secretary
Ling Ling Tang Chairman-Supervisory Board
Chao Hong Na Independent Director
Sector and Competitors